Articles in scientific journals, books, periodicals and online publications


184.) Subramani PG, Fraszczak J, Helness A, Patenaude AM, Estall J, Möröy T and Di Noia JM.
A conserved role of hnRNPL in regulating alternative splicing of transcriptional regulators necessary for B cell activation.
EMBO Reports, 2024, in press. doi:

183.) Huang Q, Curio S, Dight J, Schreuder J, Chaudhry MZ, Liao Y, Shi W, Seillet C, Jacquelot N, Tarik Möröy T, Belz GT.
GFI1B determines specificity of lung tissue resident multipotent ILC.
Science Immunology, 2024, in press.


182.) Frank D, Patnana PK, Vorwerk J, Mao L, Gopal LM, Jung N, Henning T, Frenz JM, Kuppusamy M, Autry R, Wei L, Sun K, Ahmed HMM, Künstner A, Busch H, Müller H, Hutter S, Hoermann G, Liu L, Xie X, Y Al-Matary Y, Nimmagadda SC, Cano FC, Heuser M, Thol F, Göhring G, Steinemann D, Thomale J, Leitner T, Fischer A, Rad R, Vick B, Jeremias I, Röllig C, Stölzel F, Altmann H, Kunadt D, Berdel WE, Hüve J, Neumann F, Klingauf J, Calderon V, Opalka B, Dührsen U, Rosenbauer F, Dugas M, Varghese J, Reinhardt HC, von Bubnoff N, Möröy T, Lenz G, Batcha AMN, Giorgi M, Selvam M, Wang E, McWeeney SK, Tyner JW, Mann M, Jayavelu AK and Khandanpour C.
Germline variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy.
Blood, 2023, Dec 21;142(25):2175-2191. doi: 10.1182/blood.2022015752.

181.) Möröy T and Khandanpour C.
Editorial, Frontiers in Oncology Series “New Emerging Functions of Transcription Factors and RNA-Binding Proteins in the Development of Hematological Malignancies”.
Frontiers in Oncology, 2023 Aug 1;13:1256461. doi: 10.3389/fonc.2023.1256461.

180.) Lacroix M, Beauchemin H, Khandanpour C and Möröy T.
The RNA helicase DDX3 and its role in c-MYC driven germinal center-derived B-cell lymphoma
Frontiers in Oncology, 2023, Mar 24;13:1148936. doi: 10.3389/fonc.2023.1148936.


179.) Lacroix M, Beauchemin H and Möröy T.
DDX3: a relevant therapeutic target for lymphoma?
Expert Opin Ther Targets, 2022 Dec;26(12):1037-1040. doi: 10.1080/14728222.2022.2166830.

178.) Winkler R, Mägdefrau AS, Kleemann M, Beyer M, Linke K, Hansen L, Schaffer AM, Hoffmann ME, Poepsel S, Heyd F, Beli P, Möröy T, Mahboobi S, Krämer OH and Christian Kosan
Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibition,
Oncogene, 2022, Sep;41(40):4560-4572. doi: 10.1038/s41388-022-02450-3.

177.) Lacroix M, Beauchemin H, Fraszczak J, Chen R, Shooshtarizadeh P and Möröy T.
The X-linked helicase DDX3X is required for lymphoid differentiation and MYC-driven lymphomagenesis
Cancer Research, 2022, Sep 2;82(17):3172-3186. doi: 10.1158/0008-5472.CAN-21-2454.

176.) Piskor EM, Ross J, Möröy T and Kosan C.
Myc-interacting zinc finger protein 1 (Miz 1) is essential to maintain homeostasis and immunocompetence of the B cell lineage
Biology (Basel). 2022 Mar 24;11(4):504. doi: 10.3390/biology11040504


173.) Fraszczak J and Möröy T.
The transcription factors GFI1 and GFI1B as modulators of the innate and acquired immune response.
Advances in Immunol. 2021;149:35-94. doi: 10.1016/ Epub 2021 Apr 23.

172.) Ross J, Miron CE, Plescia J, Laplante P, McBride K, Moitessier N and Möröy T.
Targeting MYC: from understanding its biology to drug discovery.
Eur J. Med Chem., 2021 Mar 5;213:113137. doi: 10.1016/j.ejmech.2020.113137.


171.) Beauchemin H and Möröy T.
Multifaceted actions of GFI1 and GFI1B in hematopoietic stem cell self-renewal and lineage commitment.
Frontiers in Genetics, 2020, Oct 26, 11:591099. doi: 10.3389/fgene.2020.591099

170.) Arman K and Möröy T.
Crosstalk between MYC and lncRNAs in hematological malignancies.
Frontiers in Oncology, 2020, Oct 8, 10:579940. doi: 10.3389/fonc.2020.579940

169.) Beauchemin H, Shooshtarizadeh P, Pinder J, Dellaire G and Möröy T.
Dominant negative Gfi1b mutations cause moderate thrombocytopenia and an impaired stress thrombopoiesis associated with mild erythropoietic abnormalities in mice.
Haematologica, 2020, Oct 1;105(10):2457-2470. doi: 10.3324/haematol.2019.222596.


168.) Khandanpour C and Möröy T.
Role of GFI1 in epigenetic regulation of MDS and AML pathogenesis: mechanisms and therapeutic implications.
Frontiers in Oncology, 2019, Aug 27; 9:824.

167.) Ross J, Rashkovan M, Fraszczak J, Joly-Beauparlant C, Vadnais C, Winkler R, Droit A, Kosan C and Möröy T.
Deletion of the Miz-1 POZ domain increases efficacy of cytarabine treatment in T- and B-ALL/lymphoma mouse models.
Cancer Research, 2019, Aug 15;79(16):4184-4195.

166.) Vadnais C, Chen R, Fraszczak J, Hamard PJ, Manfredi J and Möröy T.
A novel regulatory circuit between p53 and GFI1 controls induction of apoptosis in T cells.
Scientific Reports, 2019, Apr 19;9(1):6304.

165.) Shooshtarizadeh P, Helness A, Vadnais C, Brouwer N, Beauchemin H, Chen R, Bagci H, Staal FJT, Coté FJ and Möröy T.
Gfi1b regulates the level of Wnt/β-catenin signaling in hematopoietic stem cells and megakaryocytes
Nature Communications, 2019, Mar 20;10(1):1270.

164.) Fraszczak J, Vadnais C, Rashkovan M, Ross J, Chen R, Beauchemin H, Grapton, Khandanpour C and Möröy T.
Reduced expression but not deficiency of GFI1 causes a fatal myeloproliferative disease in mice.
Leukemia, 2019, Jan; 33(1):110-121.


163.) Vadnais C and Möröy T.
GFI1’s role in DNA repair suggests implications for tumour cell response to treatment.
Cell Stress, 2018, Vol. 2, No. 8, pp. 213 – 215;

162.) Marneth AE, Botezatu L, Hönes JM, Israël JCL, Schütte J, Lams RL, Bergevoet SM, Groothuis L, Mandoli A, Lo MC, Martens JH, Huls G, Jansen JH, Dührsen U, Berg T, Möröy T, Wichmann C, Zhang DE, an der Reijden BA, and Khandanpour C.
GFI1 is required for RUNX1/ETO positive acute myeloid leukemia.
Hematologica, 2018, Apr 19. pii: haematol.2017.180844.

161.) Vadnais C, Chen R, Fraszczak J, Yu Z, Boulais J, Pinder J, Frank D, Khandanpour C, Hébert J, Dellaire G, Côté JF, Richard S, Orthwein A, Drobetsky E and Möröy T.
GFI1 is required for efficient DNA Repair by regulating PRMT1 dependent methylation of MRE11 and 53BP1.
Nature Communications, 2018, Apr 12;9(1):1418.


160.) Beauchemin H, Shooshtarizadeh P, Vadnais C, Vassen L, Pastore Y and Möröy T.
Gfi1b controls integrin signaling-dependent cytoskeleton dynamics and organization in megakaryocytes.
Hematologica, 2017, Mar;102(3):484-497.

159.) Hansen M, Varga E, Wüst T, Brouwer N, Beauchemin H, Mellink C, van der Kevie-Kersemaekers AM, Möröy T, van der Reijden B, von Lindern M and van Akkeren E.
Generation and characterization of human iPSC line MML-6838-Cl2 from mobilized peripheral blood derived megakaryoblasts.
Stem Cell Research, 2017, (Jan)18: 26-28

158.) Fraszczak J and Möröy T.
The role of the transcriptional repressor growth factor independent 1 in the formation of myeloid cells.
Curr. Opinions in Hematology, 2017, Jan;24(1):32-37.


157.) Möröy T.
The power of Translation.
World Health Summit Yearbook, 2016 (oct), 78-79

156.) Fraszczak, Helness A, Chen R, Vadnais C, Robert F, Khandanpour C and Möröy T.
Threshold Levels of Gfi1 Maintain E2A Activity for B Cell Commitment via Repression of Id1.
PlosOne, 2016, Jul 28;11(7):e0160344.

155.) Gaudreau MC, Grapton D, Helness A, Vadnais C, Fraszczak J, Shooshtarizadeh P, Wilhelm B, Robert F, Heyd F, Möröy T.
Heterogeneous Nuclear Ribonucleoprotein L is required for the survival and functional integrity of murine hematopoietic stem cells.
Sci. Reports, 2016, June 7; 6: 27379

154.) Botezatu L, Michel LC, Helness A, Vadnais C, Makishima H, Hönes JM, Robert F, Vassen L, Thivakaran A, Al-Matary Y, Lams RF, Schütte J, Giebel B, Görgens A, Heuser M, Medyouf H, Maciejewski J, Dührsen U, Möröy T*, Khandanpour C*. (co-senior author).
Epigenetic therapy impedes leukemia progression in patients carrying the GFI136N AML predisposing gene.
Exp Hematol., 2016, Aug;44(8):713-726.e14.

153.) Botezatu L, Michel LC, Makishima H, Schroeder T, Germing U, Haas R, Bert van der Reijden B, Marneth A, Bergevoet SM, Jansen JH, Przychodzen B, Wlodarski M, Niemeyer C, Platzbecker U, Ehninger G, Unnikrishnan A, Beck D, Pimanda J, Hellström-Lindberg E, Cazzola M, Malcovati L, Boultwood J, Pellagatti A, Papaemmanuil E, Le Coutre P, Kaeda J, Opalka B, Möröy T, Dührsen U, Maciejewski J, Khandanpour C.
GFI136N as a therapeutic and prognostic marker for myelodysplastic syndrome (MDS).
Exp Hematol., 2016, Jul;44(7):590-595.e1.

152.) Thambyrajah R, Mazan M, Patel R, Moignard V, Stefanska M, Marinopoulou E, Li Y, Lancrin C, Clapes T, Möröy T, Robin C, Miller C, Cowley S, Goettgens B, Kouskoff V, and Lacaud G.
GFI1 proteins orchestrate the emergence of Haematopoietic Stem Cells through recruitment of LSD1.
Nat Cell Biol.
, 2016, Jan;18(1):21-32.

151.) Hönes JM, Botezatu L, Helness A, Vadnais C, Vassen L, Robert F, Hergenhan SM, Thivakaran A, Schütte J, Al-Matary YS, Lams RF, Fraszscak J, Makishima H, Radivoyevitch T, Przychodzen B, da Conceição Castro SV, Görgens A, Giebel B, Klein-Hitpass L, Lennartz K, Heuser M, Thiede C, Ehninger G, Dührsen U, Maciejewski J, Möröy T*, Khandanpour C*. (co-senior author).
GFI1 as a novel prognostic and therapeutic factor for AML/MDS.
Leukemia. 2016, June 30(6): 1237-45.